Evidence map›Paper›PMID 24005531›Full record

ArticlePsychopharmacology2014

Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study.

Yingfen Hsia, Angel Y S Wong, Declan G M Murphy, Emily Simonoff, Jan K Buitelaar, Ian C K Wong

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 5 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 5 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. The Effects of a 16-Week School-Based Exercise Program on Anxiety in Children with Autism Spectrum Disorder.International journal of environmental research and public health · 2022
    Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Yingfen HsiaCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China.
Angel Y S Wong
Declan G M Murphy
Emily Simonoff
Jan K Buitelaar
Ian C K Wong
King's College London · GBUniversity of Hong Kong · HKRadboud University Nijmegen · NLUniversity College London · GB

Funding

Department of Health RP-PG-0606-1045
6 · The paper itself

Abstract

rationalePrevious studies on psychotropic drugs prescribing in autism spectrum disorder (ASD) were from the USA or the UK. However, these studies may not be generalizable to other countries. There is a need to understand the extent of psychopharmacological prescribing for ASD treatment at a multinational level to identify areas of prescribing which lack evidence.

methodsWe used the IMS Prescribing Insights database to investigate psychotropic drugs prescribing patterns for ASD treatment in children and adults in 2010-2012. Data were obtained from Europe (France, Germany, Italy, Spain and UK), South America (Mexico and Brazil), North America (Canada and USA) and Asia (Japan).

resultsNorth American countries have the highest prescription rates, followed by the European and South American countries. Prescribing rates were higher in children compared to adults in individual countries. The most commonly prescribed drug for ASD was risperidone in young people (except in UK and Japan). In the UK, methylphenidate (34 %) was the most commonly prescribed for young people and haloperidol (44.1 %) in Japan. In adults, the most commonly prescribed drug class was antipsychotics and particularly risperidone (thioridazine and ziprasidone were the most prescribed antipsychotics in Brazil and USA, respectively).

conclusionThere is variation in medication prescription for people with ASD among countries, which may be attributable to diagnostic criteria, clinical guidelines or health care systems. However, there is a lack of evidence of efficacy and safety for many psychotropic drugs prescribed for people with ASD. Research is needed to bridge the evidence gaps in prescribing.

Indexed as

AdultAntipsychotic AgentsChildChild Development Disorders, PervasiveDatabases, PharmaceuticalEuropeHumansInternationalityJapanNorth AmericaPractice Patterns, Physicians'PsychopharmacologyPsychotropic DrugsSouth AmericaAntipsychotic AgentsPsychotropic Drugs

Identifiers

PMID24005531
OpenAlexW2161340827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.